Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(14%)
Results Posted
33%(2 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
2
14%
Ph not_applicable
3
21%
Ph phase_2
7
50%
Ph phase_4
1
7%
Ph phase_1
1
7%

Phase Distribution

1

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
1(7.1%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Withdrawn3
unknown2
Terminated1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 27 (50.0%)
Phase 32 (14.3%)
Phase 41 (7.1%)
N/A3 (21.4%)

Trials by Status

terminated17%
withdrawn321%
unknown214%
completed643%
active_not_recruiting17%
recruiting17%

Recent Activity

2 active trials
Showing 5 of 14
active_not_recruitingphase_2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT00092222
recruitingphase_3

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

NCT04116502
completedphase_2

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

NCT02838342
withdrawnnot_applicable

Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation

NCT03121079
unknownphase_3

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

NCT00209209
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00092222Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active Not Recruiting
NCT04116502Phase 3

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting
NCT02838342Phase 2

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

Completed
NCT03121079Not Applicable

Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation

Withdrawn
NCT00209209Phase 3

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown
NCT02027064Phase 4

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Unknown
NCT00445523Phase 2

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

Completed
NCT01146535Phase 2

Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

Completed
NCT01625793Not Applicable

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Withdrawn
NCT00838968Not Applicable

The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma

Withdrawn
NCT00329368Phase 1

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Completed
NCT00485563Phase 2

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Terminated
NCT00454181Phase 2

Treatment of Oral Warts in HIV+ Patients

Completed
NCT00895947Phase 2

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14